NPPB and left ventricular hypertrophy: The ESES-LVH study [25], one of the five clinical studies used in this pooled analysis, showed the cardioprotective effects of esaxerenone based on the reduction in NT-proBNP and left ventricular mass index (LVMI) in hypertensive patients with left ventricular hypertrophy.